Fair Value Measurements - Contingent Consideration (Details) - USD ($) |
1 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|
Sep. 30, 2022 |
Jan. 31, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Oct. 06, 2021 |
Feb. 25, 2019 |
|
Fair Value Measurements | ||||||
Contingent consideration under RPAs and CPPAs | $ 75,000 | $ 8,075,000 | ||||
Bioasis | Royalty Purchase Agreement | ||||||
Fair Value Measurements | ||||||
Changes in estimated fair value of contingent consideration | 0 | |||||
Contingent consideration under RPAs and CPPAs | 100,000 | $ 100,000 | ||||
Payments of contingent consideration | 0 | |||||
Affitech | Commercial Payment Purchase Agreement | ||||||
Fair Value Measurements | ||||||
Contingent consideration under RPAs and CPPAs | $ 0 | $ 8,000,000.0 | $ 8,000,000.0 | |||
Payments of contingent consideration | $ 3,000,000.0 | $ 5,000,000.0 |
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition Changes in estimated fair value of contingent consideration. No definition available.
|
X | ||||||||||
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements. No definition available.
|
X | ||||||||||
- Definition Payments of contingent consideration. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|